Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1001
-
1002
-
1003
-
1004
-
1005
-
1006
-
1007
-
1008
-
1009
The Anion [Mg<sub>6</sub>Cl<sub>8</sub>Cp*<sub>5</sub>]<sup>-</sup>: A Final Intermediate on the Way to the Molecular Donor-Free Grignard Compound MgClCp*?
Published 2006“…At a slightly higher temperature and by stepwise decrease of the diethyl ether concentration before reaction, a preferred formation of metal clusters such as dodekakispentamethylcyclopentadienylpentaconta-aluminum, Al<sub>50</sub>Cp*<sub>12</sub>, was frequently observed. …”
-
1010
-
1011
-
1012
-
1013
-
1014
-
1015
Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif
Published 2021“…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
-
1016
-
1017
-
1018
-
1019
The TLR4 activator LPS decreases photoreceptor viability and reducesWnt-mediated protection from oxidative stress.
Published 2012“…White bars, no H<sub>2</sub>O<sub>2</sub>; black bars, with H<sub>2</sub>O<sub>2</sub>. Mean ± SD, *p<0.05 no additions with H<sub>2</sub>O<sub>2</sub> (n = 5) compared with Wnt3a (n = 4); #p<0.05 50 µg/ml LPS+Wnt3a (n = 5) compared with Wnt3a+ H<sub>2</sub>O<sub>2</sub> (n = 4). …”
-
1020
DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”